Loren Clarke, MD, vice president of Medical Affairs of Dermatology at Myriad Genetics, discusses melanoma biopsies.

There are approximately 1.5 million biopsies performed in the United States each year for atypical moles, Clarke says. These biopsies are done to exclude the possibility of melanoma, though about 15% are difficult to diagnose.

The myPath test, developed by Myriad Genetics, is an objective 23-gene signature assay that helps in the differentiation of malignant melanoma and a benign nevus.

Loren Clarke, MD

Articles

Dr. Clarke on Melanoma Biopsies